Clinical trial
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic…
NCT00079326 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00079326 |
|---|---|
| Title | Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer |
| Official title | A Phase 2 Study of Trastuzumab in Combination With BMS-247550 in Women With Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | trastuzumab, ixabepilone, laboratory biomarker analysis |
| Enrollment | 39 |
| Start date | Jan 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Oct 1, 2010 |
| First posted | Mar 10, 2004 |
| Last update posted | Jun 2, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: